Back to search

University of Sheffield

The Development of a Novel Strategy to Target Dormant Myeloma Cells by Standard of Care Therapy

Abstract

dc:description.abstract

Introduction: Multiple myeloma is an incurable disease caused by the abnormal growth of plasma cells in the bone marrow and characterised by hypercalcaemia, renal insufficiency, anaemia, and lytic bone disease. Despite current treatments debulking the majority of tumour burden, disease relapse often occurs due to minimal residual disease (MRD), including dormant myeloma cells (DMCs). DMCs can remain inactive for years before being reactivated by the bone microenvironment (BMME). Previous studies have revealed a crosstalk between DMCs in the BMME, and several biomarkers have been discovered (e.g., AXL, TRIM44). However, currently, there is limited knowledge of the effects of myeloma standard of care (SoC) therapies on DMCs. We hypothesised that DMCs would be targeted more effectively by combined SoC therapies than monotherapy. To test this hypothesis, both in vitro and in vivo model systems were used. Methodology: In vitro studies were performed using myeloma cell lines (5TGM1, JJN3, OPM2, and U266) transduced previously with GFP and/or Luc. Cells were also labelled with a vybrant membrane dye (DID) to measure and identify DMCs. Flow cytometry and fluorescent imaging were used to determine optimum time points for drug evaluation on DMCs. Drug assays were then performed by treating myeloma cells over time with SoC therapies with different mechanisms of action: Bortezomib (Btz) is a reversible proteosome inhibitor (PI), Pomalidomide (Pom) is an immunomodulatory (IMiD), Melphalan (Mel) is a bifunctional alkylating agent, and Panobinostat (Pan) is a histone deacetylase inhibitor (HDACi). Drug IC50 values were determined and then used to assess the most effective drug combination to target DMCs in vitro and in vivo. Results: Fluorescent imaging and flow cytometry showed the presence of DIDhigh cells (potential DMCs) over 21 days in the in vitro culture of all four myeloma cell lines. JJN3-DIDhigh cells were sensitive to single treatments and the combination of Btz and Pan compared to single Btz, and OPM2-DIDhigh were sensitive to single drugs and to the combination of Btz /Mel compared to Btz, Btz/ Pan compared to Btz, and Mel/ Pan compared to Mel. NSG mice injected with JJN3-GFP-Luc-DID cells and treated with Btz and/or Pan showed that Btz reduced tumour burden and increased osteoblasts (OB), thus increasing DMCs. Conclusion: DMCs were present in all myeloma cell cultures, combined treatment was more effective than monotherapy in vitro. The in vivo showed someiv combinations reduced the tumour burden but resulted an increase in DMCs. These unexpected results remain inconclusive and require further investigation.

Degree

thesis:*
Name dc:type.qualificationname
Ph.D
Level dc:type.qualificationlevel
doctoral
Grantor dc:publisher.institution
University of Sheffield
Year dc:date.issued
2024

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Algifry, Hawazen
Advisors dc:contributor.advisor
  • Lawson, Michelle
  • Muthana, Munitta

Rights

Language dc:language.dcterms_iso639_2
eng

Identifiers

dc:identifier.*
Dc Identifier Grantnumber
1015048273

Chain of custody

source
Harvested from
White Rose University Consortium
Base URL
etheses.whiterose.ac.uk/cgi/oai2
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Algifry, Hawazen. The Development of a Novel Strategy to Target Dormant Myeloma Cells by Standard of Care Therapy. doctoral thesis, University of Sheffield, 2024.